Literature DB >> 6196463

Past infectious events and disease evolution in multiple sclerosis.

G Lamoureux, Y Lapierre, G Ducharme.   

Abstract

A computerized study of past infectious events and neurological parameters revealed the existence of a history of repeated respiratory-tract infections (RRI) beginning in childhood, in 52% of 251 multiple sclerosis (MS) patients studied. The 251 MS patients were divided into two groups: those without a past history of RRI were designated as "MS type I", and those with a history of infectious problems before the onset of MS as "MS type II". Significant differences in the neurological symptoms, the treatment received and some general parameters were found between the groups, which suggested a correlation between the evolution of MS and the presence or not of RRI in these patients. When compared to the MS type I group, a significantly higher percentage of MS type II patients reported visual problems (P less than or equal to 0.01), paresthesia (P less than or equal to 0.01), loss of sensitivity (P less than or equal to 0.03), pain (P less than or equal to 0.004), motor problems (P less than or equal to 0.016) and sexual dysfunction in males (P less than or equal to 0.02). The mean number of attacks in the first 5 years of the disease was significantly more frequent in MS type II patients, 6.2 compared to 2.9 (P less than or equal to 0.02). A significantly higher percentage of MS type II patients also received oral corticosteroids (P less than or equal to 0.02) or ACTH (P less than or equal to 0.003). Although the age of onset of MS was the same for both groups, MS type II patients were significantly younger than MS type I patients, the mean age being 36 years compared to 41 years (P less than or equal to 0.001). Only 12% of patients in the MS type II group compared to 30% in the MS type I group had the disease for more than 15 years (P less than or equal to 0.001). As is usual with MS, the majority of the patients in both groups were females, 79.3% in the MS type II compared to 63.4% in the MS type I group. These findings suggest that MS patients with a past history of RRI (MS type II) have a different evolution of their disease from MS type I patients and that in general the disease is more severe. The past infectious history of patients would thus appear of putative value, in addition to neurological criteria, in assessing the probable future evolution of the disease.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6196463     DOI: 10.1007/bf00313635

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  17 in total

1.  Measles antibodies in multiple sclerosis.

Authors:  J M ADAMS; D T IMAGAWA
Journal:  Proc Soc Exp Biol Med       Date:  1962-12

2.  PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS.

Authors:  G A SCHUMACHER; G BEEBE; R F KIBLER; L T KURLAND; J F KURTZKE; F MCDOWELL; B NAGLER; W A SIBLEY; W W TOURTELLOTTE; T L WILLMON
Journal:  Ann N Y Acad Sci       Date:  1965-03-31       Impact factor: 5.691

3.  Epidemiology of multiple sclerosis and a possible virus aetiology.

Authors:  J A Brody
Journal:  Lancet       Date:  1972-07-22       Impact factor: 79.321

4.  Prior events in multiple sclerosis.

Authors:  R D Currier; E A Martin; P C Woosley
Journal:  Neurology       Date:  1974-08       Impact factor: 9.910

5.  Virus antibodies in serum specimens from patients with multiple sclerosis, from siblings, and matched controls. A final report.

Authors:  M Panelius; A Salmi; P E Halonen; E Kivalo; U K Rinne; K Penttinen
Journal:  Acta Neurol Scand       Date:  1973       Impact factor: 3.209

6.  Suppressor cell function in multiple sclerosis: correlation with clinical disease activity.

Authors:  J P Antel; B G Arnason; M E Medof
Journal:  Ann Neurol       Date:  1979-04       Impact factor: 10.422

7.  Natural killer cell activity in patients with multiple sclerosis: interferon and plasmapheresis.

Authors:  A Uchida; E M Maida; R Lenzhofer; M Micksche
Journal:  Immunobiology       Date:  1982-02       Impact factor: 3.144

8.  Immunologic mechanisms in multiple sclerosis. Exacerbation by type A hepatitis and skin test antigens.

Authors:  R L Owen; P C Dau; K P Johnson; L E Spitler
Journal:  JAMA       Date:  1980-11-21       Impact factor: 56.272

9.  Dysfunction of natural killer cells in multiple sclerosis: a possible pathogenetic factor.

Authors:  M Benczur; G G Petrányl; G Pálffy; M Varga; M Tálas; B Kotsy; I Földes; S R Hollán
Journal:  Clin Exp Immunol       Date:  1980-03       Impact factor: 4.330

10.  Risk factors in multiple sclerosis: tuberculin reactivity, age at measles infection, tonsillectomy and appendectomy.

Authors:  E Andersen; H Isager; K Hyllested
Journal:  Acta Neurol Scand       Date:  1981-02       Impact factor: 3.209

View more
  3 in total

1.  HLA antigens-linked genetic control in multiple sclerosis patients resistant and susceptible to infection.

Authors:  G Lamoureux; P Duquette; Y Lapierre; B Cosgrove; G Bourret; L Labrie
Journal:  J Neurol       Date:  1983       Impact factor: 4.849

2.  Immunological treatment of multiple sclerosis.

Authors:  R A Hughes
Journal:  J Neurol       Date:  1983       Impact factor: 4.849

3.  Onset Symptom Clusters in Multiple Sclerosis: Characteristics, Comorbidities, and Risk Factors.

Authors:  Vladeta Ajdacic-Gross; Nina Steinemann; Gábor Horváth; Stephanie Rodgers; Marco Kaufmann; Yanhua Xu; Christian P Kamm; Jürg Kesselring; Zina-Mary Manjaly; Chiara Zecca; Pasquale Calabrese; Milo A Puhan; Viktor von Wyl
Journal:  Front Neurol       Date:  2021-07-06       Impact factor: 4.003

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.